@article{Folasade_Dele-Ojo_B-2024_168204,
title = {Short-term COVID-19 vaccine adverse effects among adults in Ekiti State, Nigeria},
author = {Folasade Dele-Ojo, B. and Adesokan, A. and Fadare, J. and Ajayi, P. and Raimi, T. and Dada, S. and Dele, O. and Ogunmodede, J. and Ipinimo, T. and Ariyo, O. and Godman, B.},
month = {feb},
year = {2024},
abstract = {Background: The safety of the COVID-19 vaccines has been a topic of concern globally. This issue of safety is associated with vaccine hesitancy due to concerns about the adverse effects of the vaccines. Consequently, this study determined the short-term safety profile of the Oxford/AstraZeneca COVID-19 vaccine in Ekiti State, Nigeria. Methods: Descriptive cross-sectional study conducted between May and July 2021 among individuals who had received the first dose of the first batch of the Oxford/AstraZeneca COVID-19 vaccine at Ekiti State University Teaching Hospital (EKSUTH), Ado-Ekiti, Nigeria. A Google form was used to collect data on the adverse effects of the vaccine. Results: Out of over 1,000 individuals who were approached, 758 respondents completed the study. A large percentage (57.4%) of those who received the vaccines were healthcare workers. Adverse effects were reported in 70.8% of the participants with most manifesting on the first day of the vaccination. The predominant adverse effects were injection site soreness (28.5%), followed by fatigue (18.7%) and muscle pain (8.6%). There was no report of severe adverse effects such as anaphylactic reactions, thrombosis, myocarditis, transient myelitis, or Guillen-Barre syndrome. Conclusion: This study found that self-reported adverse effects of the Oxford/AstraZeneca COVID-19 vaccine were mild and short in duration. This outcome has promising implications for improving COVID-19 vaccine uptake in the immediate environment and Nigeria.},
journal = {Current Medical Research and Opinion},
publisher = {Taylor and Francis},
url = {https://doi.org/10.1080/03007995.2024.2316217},
}
